Green light for Berlin Center for Gene and Cell Therapies to be operated by Bayer and Charité
On the Bayer campus in Berlin, the new Berlin Center for Gene and Cell Therapies will be built based on the design conceived by HENN. This joint project of Bayer AG and Charité – Universitätsmedizin Berlin is designed as a start-up incubator with integrated production facilities to create a biotech ecosystem for novel treatment options using gene and cell therapies. Last Friday, the plans were presented to the public in the presence of Federal Chancellor Olaf Scholz. The project will receive funds from the Federal Ministry of Education and Research and from the State of Berlin. Construction is scheduled to commence in 2025 under the head responsibility of iQ spaces.
The new Berlin Center for Gene and Cell Therapies will provide a working environment for up to 900 people. At the center, researchers will be working to develop new medicines that can be made available more quickly to patients.
Martin Henn, Managing Director and Design Principal at HENN, comments:
“Our design for the Berlin Center for Gene and Cell Therapies combines research, development, and production at the heart of the German capital. Geared towards interdisciplinary ways of working and tasks, it will put people in the focus while making the research topics being investigated tangible to the surrounding community. The new build’s transparent design embodies the concept of ‘Science on Display’.”
